Inhibition of cytochrome P450 2B6 activity by voriconazole profiled using efavirenz disposition in healthy volunteers

Zeruesenay Desta, Ingrid F. Metzger, Nancy Thong, Jessica B L Lu, John Callaghan, Todd Skaar, David A. Flockhart, Raymond E. Galinsky

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cytochrome P450 2B6 (CYP2B6) metabolizes clinically important drugs and other compounds. Its expression and activity vary widely among individuals, but quantitative estimation is hampered by the lack of safe and selective in vivo probes of CYP2B6 activity. Efavirenz, a nonnucleoside HIV-1 reverse transcriptase inhibitor, is mainly cleared by CYP2B6, an enzyme strongly inhibited in vitro by voriconazole. To test efavirenz metabolism as an in vivo probe of CYP2B6 activity, we quantified the inhibition of CYP2B6 activity by voriconazole in 61 healthy volunteers administered a single 100-mg oral dose of efavirenz with and without voriconazole administration. The kinetics of efavirenz metabolites demonstrated formation rate-limited elimination. Compared to control, voriconazole prolonged the elimination half-life (t1/2) and increased both the maximum concentration of drug in serum (Cmax) and the area under the concentration-time curve from 0 h to t (AUC0-t) of efavirenz (mean change of 51%, 36%, and 89%, respectively) (P<0.0001) with marked intersubject variability (e.g., the percent change in efavirenz AUC0-t ranged from 0.4% tõ224%). Voriconazole decreased efavirenz 8-hydroxylation by greater than 60% (P<0.0001), whereas its effect on 7-hydroxylation was marginal. The plasma concentration ratio of efavirenz to 8-hydroxyefavirenz, determined 1 to 6 h after dosing, was significantly increased by voriconazole and correlated with the efavirenz AUC0-t (Pearson r=>0.8; P< 0.0001). This study demonstrates the mechanisms of voriconazole-efavirenz interaction, establishes the use of a low dose of efavirenz as a safe and selective in vivo probe for phenotyping CYP2B6 activity, and identifies several easy-to-use indices that should enhance understanding of the mechanisms of CYP2B6 interindividual variability.

Original languageEnglish (US)
Pages (from-to)6813-6822
Number of pages10
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

efavirenz
Healthy Volunteers
Reverse Transcriptase Inhibitors
Cytochrome P-450 CYP2B6
Voriconazole
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Half-Life

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Inhibition of cytochrome P450 2B6 activity by voriconazole profiled using efavirenz disposition in healthy volunteers. / Desta, Zeruesenay; Metzger, Ingrid F.; Thong, Nancy; Lu, Jessica B L; Callaghan, John; Skaar, Todd; Flockhart, David A.; Galinsky, Raymond E.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 11, 01.11.2016, p. 6813-6822.

Research output: Contribution to journalArticle

Desta, Zeruesenay ; Metzger, Ingrid F. ; Thong, Nancy ; Lu, Jessica B L ; Callaghan, John ; Skaar, Todd ; Flockhart, David A. ; Galinsky, Raymond E. / Inhibition of cytochrome P450 2B6 activity by voriconazole profiled using efavirenz disposition in healthy volunteers. In: Antimicrobial Agents and Chemotherapy. 2016 ; Vol. 60, No. 11. pp. 6813-6822.
@article{a5208f47078a41c6a21bb01a4d6e5562,
title = "Inhibition of cytochrome P450 2B6 activity by voriconazole profiled using efavirenz disposition in healthy volunteers",
abstract = "Cytochrome P450 2B6 (CYP2B6) metabolizes clinically important drugs and other compounds. Its expression and activity vary widely among individuals, but quantitative estimation is hampered by the lack of safe and selective in vivo probes of CYP2B6 activity. Efavirenz, a nonnucleoside HIV-1 reverse transcriptase inhibitor, is mainly cleared by CYP2B6, an enzyme strongly inhibited in vitro by voriconazole. To test efavirenz metabolism as an in vivo probe of CYP2B6 activity, we quantified the inhibition of CYP2B6 activity by voriconazole in 61 healthy volunteers administered a single 100-mg oral dose of efavirenz with and without voriconazole administration. The kinetics of efavirenz metabolites demonstrated formation rate-limited elimination. Compared to control, voriconazole prolonged the elimination half-life (t1/2) and increased both the maximum concentration of drug in serum (Cmax) and the area under the concentration-time curve from 0 h to t (AUC0-t) of efavirenz (mean change of 51{\%}, 36{\%}, and 89{\%}, respectively) (P<0.0001) with marked intersubject variability (e.g., the percent change in efavirenz AUC0-t ranged from 0.4{\%} t{\~o}224{\%}). Voriconazole decreased efavirenz 8-hydroxylation by greater than 60{\%} (P<0.0001), whereas its effect on 7-hydroxylation was marginal. The plasma concentration ratio of efavirenz to 8-hydroxyefavirenz, determined 1 to 6 h after dosing, was significantly increased by voriconazole and correlated with the efavirenz AUC0-t (Pearson r=>0.8; P< 0.0001). This study demonstrates the mechanisms of voriconazole-efavirenz interaction, establishes the use of a low dose of efavirenz as a safe and selective in vivo probe for phenotyping CYP2B6 activity, and identifies several easy-to-use indices that should enhance understanding of the mechanisms of CYP2B6 interindividual variability.",
author = "Zeruesenay Desta and Metzger, {Ingrid F.} and Nancy Thong and Lu, {Jessica B L} and John Callaghan and Todd Skaar and Flockhart, {David A.} and Galinsky, {Raymond E.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1128/AAC.01000-16",
language = "English (US)",
volume = "60",
pages = "6813--6822",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Inhibition of cytochrome P450 2B6 activity by voriconazole profiled using efavirenz disposition in healthy volunteers

AU - Desta, Zeruesenay

AU - Metzger, Ingrid F.

AU - Thong, Nancy

AU - Lu, Jessica B L

AU - Callaghan, John

AU - Skaar, Todd

AU - Flockhart, David A.

AU - Galinsky, Raymond E.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Cytochrome P450 2B6 (CYP2B6) metabolizes clinically important drugs and other compounds. Its expression and activity vary widely among individuals, but quantitative estimation is hampered by the lack of safe and selective in vivo probes of CYP2B6 activity. Efavirenz, a nonnucleoside HIV-1 reverse transcriptase inhibitor, is mainly cleared by CYP2B6, an enzyme strongly inhibited in vitro by voriconazole. To test efavirenz metabolism as an in vivo probe of CYP2B6 activity, we quantified the inhibition of CYP2B6 activity by voriconazole in 61 healthy volunteers administered a single 100-mg oral dose of efavirenz with and without voriconazole administration. The kinetics of efavirenz metabolites demonstrated formation rate-limited elimination. Compared to control, voriconazole prolonged the elimination half-life (t1/2) and increased both the maximum concentration of drug in serum (Cmax) and the area under the concentration-time curve from 0 h to t (AUC0-t) of efavirenz (mean change of 51%, 36%, and 89%, respectively) (P<0.0001) with marked intersubject variability (e.g., the percent change in efavirenz AUC0-t ranged from 0.4% tõ224%). Voriconazole decreased efavirenz 8-hydroxylation by greater than 60% (P<0.0001), whereas its effect on 7-hydroxylation was marginal. The plasma concentration ratio of efavirenz to 8-hydroxyefavirenz, determined 1 to 6 h after dosing, was significantly increased by voriconazole and correlated with the efavirenz AUC0-t (Pearson r=>0.8; P< 0.0001). This study demonstrates the mechanisms of voriconazole-efavirenz interaction, establishes the use of a low dose of efavirenz as a safe and selective in vivo probe for phenotyping CYP2B6 activity, and identifies several easy-to-use indices that should enhance understanding of the mechanisms of CYP2B6 interindividual variability.

AB - Cytochrome P450 2B6 (CYP2B6) metabolizes clinically important drugs and other compounds. Its expression and activity vary widely among individuals, but quantitative estimation is hampered by the lack of safe and selective in vivo probes of CYP2B6 activity. Efavirenz, a nonnucleoside HIV-1 reverse transcriptase inhibitor, is mainly cleared by CYP2B6, an enzyme strongly inhibited in vitro by voriconazole. To test efavirenz metabolism as an in vivo probe of CYP2B6 activity, we quantified the inhibition of CYP2B6 activity by voriconazole in 61 healthy volunteers administered a single 100-mg oral dose of efavirenz with and without voriconazole administration. The kinetics of efavirenz metabolites demonstrated formation rate-limited elimination. Compared to control, voriconazole prolonged the elimination half-life (t1/2) and increased both the maximum concentration of drug in serum (Cmax) and the area under the concentration-time curve from 0 h to t (AUC0-t) of efavirenz (mean change of 51%, 36%, and 89%, respectively) (P<0.0001) with marked intersubject variability (e.g., the percent change in efavirenz AUC0-t ranged from 0.4% tõ224%). Voriconazole decreased efavirenz 8-hydroxylation by greater than 60% (P<0.0001), whereas its effect on 7-hydroxylation was marginal. The plasma concentration ratio of efavirenz to 8-hydroxyefavirenz, determined 1 to 6 h after dosing, was significantly increased by voriconazole and correlated with the efavirenz AUC0-t (Pearson r=>0.8; P< 0.0001). This study demonstrates the mechanisms of voriconazole-efavirenz interaction, establishes the use of a low dose of efavirenz as a safe and selective in vivo probe for phenotyping CYP2B6 activity, and identifies several easy-to-use indices that should enhance understanding of the mechanisms of CYP2B6 interindividual variability.

UR - http://www.scopus.com/inward/record.url?scp=84995477356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995477356&partnerID=8YFLogxK

U2 - 10.1128/AAC.01000-16

DO - 10.1128/AAC.01000-16

M3 - Article

C2 - 27600044

AN - SCOPUS:84995477356

VL - 60

SP - 6813

EP - 6822

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -